Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
49 results
  • Lung Cancer

22-323          Phase II

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

  • Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Prostate Cancer, Breast Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

  • Lung Cancer

17-028          Phase II

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

  • Gastric (Stomach) Cancer, Lung Cancer, Melanoma, Pancreatic Cancer

24-058          Phase II

A Phase 1/2a Study of IMM-6-415 in Participants with Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations

  • Kidney Cancer, Lung Cancer, Ovarian Cancer, Head and Neck Cancer, Breast Cancer, Bladder Cancer, Melanoma

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors

  • Colorectal Cancer, Lung Cancer

21-398          Phase I

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

24-649          Phase I

A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors

  • Breast Cancer, Lung Cancer, Colorectal Cancer

24-514          Phase I

A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)

  • Lung Cancer

22-331          Phase II

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib

  • Ovarian Cancer, Lung Cancer, Breast Cancer, Hematology

19-642          Phase III

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Showing 21 - 30 of 49 results